Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Hormone Deficiency Market’s Growth Rate Evolve Over the Forecast Period to 2034?

In recent times, the market size for growth hormone deficiency has seen robust growth. It is estimated to expand from $4.06 billion in 2024 to $4.31 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. Factors that can be credited for this historic growth include a rise in strategic initiatives, an increase in brain tumor cases, a growing demand for hormone therapies, a surge in the elderly population, and an increase in government healthcare funding.

Expectations are high for robust expansion in the growth hormone deficiency market in the forthcoming years, with predictions placing it at a value of $5.42 billion by 2029, thanks to a compound annual growth rate (CAGR) of 5.9%. This expected surge in the forecast period can be related to an increase in genetic disorders, strategic initiatives on the rise, amplified research and development, increased cases of Gh disease, and a substantial rise in clinical trials. Key trends projected for the forecast period encompass advancements in technology, greater treatment choices, enhancements in diagnostic procedures, recent forward strides, and breakthroughs in biotechnology.

Which Major Market Drivers Are Expected to Boost the Growth Hormone Deficiency Market’s Growth Potential?

The increasing occurrence of genetic anomalies is predicted to bolster the expansion of the growth hormone deficiency market. These anomalies denote health issues triggered by irregularities or changes in an individual’s DNA, which can be hereditary or develop randomly. Factors contributing to the rise in genetic anomalies include improved diagnostic technology, heightened awareness, increased maternal age, mutation-causing environmental aspects, population expansion, and enhanced survival rates for impacted persons. Growth hormone deficiency is utilized to handle growth issues in certain genetic conditions. For instance, a study released in December 2022 by the Department of Health & Social Care (DHSC), a governmental department based in the UK, suggested that approximately 33,000 whole genome equivalents were sequenced in October 2022, boasting an average diagnostic yield of 32% that peaked at 61% under specific circumstances. Thus, the increasing occurrence of genetic anomalies propels the expansion of the growth hormone deficiency market.

Explore Comprehensive Insights Into The Global Growth Hormone Deficiency Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21197&type=smp

Who Are the Influential Players Reshaping the Growth Hormone Deficiency Market Landscape?

Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

What New and Evolving Trends Are Having a Lasting Impact on the Growth Hormone Deficiency Market?

Major players in the deficiency of the growth hormone market are concentrating their efforts on the creation of innovative products like unmodified somatropin, aiming towards daily treatments for pediatric growth hormone deficiency (GHD). Unmodified somatropin is essentially the same growth hormone used in daily pediatric GHD treatment, except it’s now available in a once-weekly dose courtesy of Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, introduced SKYTROFA (lonapegsomatropin) as a one week treatment for pediatric GHD. This revolutionary therapy provides superior convenience, increased compliance, and potentially more effective treatment results than traditional daily growth hormone therapies. It stands as the only FDA-approved once-weekly treatment for pediatric GHD, marking it as a pioneering progression in endocrinology and pediatric care.

Secure Your Global Growth Hormone Deficiency Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/growth-hormone-deficiency-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Growth Hormone Deficiency Market?

The growth hormone deficiency market covered in this report is segmented –

1) By Type: Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency

2) By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery

3) By Route Of Administration: Intravenous, Intramuscular, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency, Genetic Growth Hormone Deficiency, Acquired Growth Hormone Deficiency

2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency, Secondary Growth Hormone Deficiency

Which Geographic Locations Are Critical to the Growth of the Growth Hormone Deficiency Market?

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Growth Hormone Deficiency Market?

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

Browse Through More Similar Reports By The Business Research Company:

Cholesterol Test Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cholesterol-test-global-market-report

Antibody Contract Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Global Market Report 2025

https://thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: